# Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

> **NCT01533948** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 25 (actual)

## Conditions studied

- Extraocular Extension Melanoma
- Metastatic Intraocular Melanoma
- Recurrent Intraocular Melanoma
- Recurrent Melanoma
- Stage IIIA Intraocular Melanoma
- Stage IIIA Melanoma
- Stage IIIB Intraocular Melanoma
- Stage IIIB Melanoma
- Stage IIIC Intraocular Melanoma
- Stage IIIC Melanoma
- Stage IV Intraocular Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** axitinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01533948
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2018-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01533948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01533948, "Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01533948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*